Last 12 months
Inside the activity.
0 purchase rows · 15 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2024 Filed May 24, 2024 20:22 UTC |
KRANTZ DONALD GDirector
|
GrantCommon Stock | 4,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-018335 · rdgdoc.xml · nonDerivative · entry 1 KRANTZ DONALD G · CIK 0001183159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,714 F1 · shares: Restricted stock units ("RSUs") that vest in full on the date of the 2025 Annual Meeting of Shareholders, provided that the date of the 2025 Annual Meeting of Shareholders is at least 50 weeks after the date of the grant. Read SEC document |
| May 23, 2024 Filed May 24, 2024 20:22 UTC |
WEHRWEIN SVENDirector
|
GrantCommon Stock | 4,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-018334 · rdgdoc.xml · nonDerivative · entry 1 WEHRWEIN SVEN · CIK 0001205069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,356 F1 · shares: Deferred stock units ("DSUs") that vest in full on the date of the 2025 Annual Meeting of Shareholders, provided that the date of the 2025 Annual Meeting of Shareholders is at least 50 weeks after the date of the grant. DSUs must be retained by the reporting person until the completion of the reporting person's service on the Company's Board of Directors. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:24 UTC |
Kenison Michael R.VP and GM of the America's
|
Tax withholdingCommon Stock | 336 | $31.81 | $10,688.16 |
DisclosureSEC source: 0001437749-24-018009 · rdgdoc.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,351 F1 · balance_after: Includes 282 shares of Common Stock of the issuer purchased on May 15, 2024 through the issuer's Employee Stock Purchase Plan program. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:23 UTC |
Schumacher DanielChief Financial Officer
|
Tax withholdingCommon Stock | 370 | $31.81 | $11,769.70 |
DisclosureSEC source: 0001437749-24-018007 · rdgdoc.xml · nonDerivative · entry 1 Schumacher Daniel · CIK 0001894753 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,130 Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:06 UTC |
Kenison Michael R.VP and GM of the America's
|
GrantEmployee Stock Option (right to buy) · Derivative | 7,555 | $0.00 Strike: $33.52 | $0.00 |
DisclosureSEC source: 0001437749-24-004398 · rdgdoc.xml · derivative · entry 3 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,555 Underlying: Common Stock · 7,555 shares Expires 2034-02-13 F3 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:06 UTC |
Kenison Michael R.VP and GM of the America's
|
GrantCommon Stock | 8,205 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-004398 · rdgdoc.xml · nonDerivative · entry 2 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,405 F2 · shares: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:06 UTC |
Kenison Michael R.VP and GM of the America's
|
Tax withholdingCommon Stock | 1,070 | $33.52 | $35,866.40 |
DisclosureSEC source: 0001437749-24-004398 · rdgdoc.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,200 F1 · balance_after: Includes 349 shares of Common Stock of the issuer purchased on May 15, 2023 and 197 shares of Common Stock of the issuer purchased on November 15, 2023, through the issuer's Employee Stock Purchase Plan program. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:07 UTC |
Schumacher DanielChief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 9,616 | $0.00 Strike: $33.52 | $0.00 |
DisclosureSEC source: 0001437749-24-004400 · rdgdoc.xml · derivative · entry 3 Schumacher Daniel · CIK 0001894753 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,616 Underlying: Common Stock · 9,616 shares Expires 2034-02-13 F2 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:07 UTC |
Schumacher DanielChief Financial Officer
|
GrantCommon Stock | 5,221 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-004400 · rdgdoc.xml · nonDerivative · entry 2 Schumacher Daniel · CIK 0001894753 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 F1 · shares: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:07 UTC |
Schumacher DanielChief Financial Officer
|
Tax withholdingCommon Stock | 1,018 | $33.52 | $34,123.36 |
DisclosureSEC source: 0001437749-24-004400 · rdgdoc.xml · nonDerivative · entry 1 Schumacher Daniel · CIK 0001894753 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,279 Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:08 UTC |
Klaas BjoernVP and Mng Director-PL Europe
|
GrantEmployee Stock Option (right to buy) · Derivative | 6,182 | $0.00 Strike: $33.52 | $0.00 |
DisclosureSEC source: 0001437749-24-004402 · rdgdoc.xml · derivative · entry 3 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,182 Underlying: Common Stock · 6,182 shares Expires 2034-02-13 F2 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:08 UTC |
Klaas BjoernVP and Mng Director-PL Europe
|
GrantCommon Stock | 6,713 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-004402 · rdgdoc.xml · nonDerivative · entry 2 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,046 F1 · shares: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:08 UTC |
Klaas BjoernVP and Mng Director-PL Europe
|
Tax withholdingCommon Stock | 1,741 | $33.52 | $58,358.32 |
DisclosureSEC source: 0001437749-24-004402 · rdgdoc.xml · nonDerivative · entry 1 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,333 Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:04 UTC |
Ryaboy OlegChief Technology Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 9,616 | $0.00 Strike: $33.52 | $0.00 |
DisclosureSEC source: 0001437749-24-004396 · rdgdoc.xml · derivative · entry 3 Ryaboy Oleg · CIK 0001945827 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,616 Underlying: Common Stock · 9,616 shares Expires 2034-02-13 F3 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:04 UTC |
Ryaboy OlegChief Technology Officer
|
GrantCommon Stock | 10,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-004396 · rdgdoc.xml · nonDerivative · entry 2 Ryaboy Oleg · CIK 0001945827 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,497 F2 · shares: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:04 UTC |
Ryaboy OlegChief Technology Officer
|
Tax withholdingCommon Stock | 1,702 | $33.52 | $57,051.04 |
DisclosureSEC source: 0001437749-24-004396 · rdgdoc.xml · nonDerivative · entry 1 Ryaboy Oleg · CIK 0001945827 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,055 F1 · balance_after: Includes 1,097 shares of Common Stock of the issuer purchased on May 15, 2023 and 797 shares of Common Stock of the issuer purchased on November 15, 2023 through the issuer's Employee Stock Purchase Plan program. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:03 UTC |
Bodor RobertPresident and CEO
|
GrantEmployee Stock Option (right to buy) · Derivative | 41,209 | $0.00 Strike: $33.52 | $0.00 |
DisclosureSEC source: 0001437749-24-004394 · rdgdoc.xml · derivative · entry 3 Bodor Robert · CIK 0001581088 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,209 Underlying: Common Stock · 41,209 shares Expires 2034-02-13 F3 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:03 UTC |
Bodor RobertPresident and CEO
|
GrantCommon Stock | 22,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-004394 · rdgdoc.xml · nonDerivative · entry 2 Bodor Robert · CIK 0001581088 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,703 F2 · shares: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:03 UTC |
Bodor RobertPresident and CEO
|
Tax withholdingCommon Stock | 3,548 | $33.52 | $118,928.96 |
DisclosureSEC source: 0001437749-24-004394 · rdgdoc.xml · nonDerivative · entry 1 Bodor Robert · CIK 0001581088 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,328 F1 · balance_after: Includes 1,097 shares of Common Stock of the issuer purchased on May 15, 2023 and 1 share of Common Stock of the issuer purchased on November 15, 2023 through the issuer's Employee Stock Purchase Plan program. Read SEC document |
| May 20, 2023 Filed May 23, 2023 20:22 UTC |
Schumacher DanielChief Financial Officer
|
Tax withholdingCommon Stock | 418 | $32.36 | $13,526.48 |
DisclosureSEC source: 0001437749-23-015592 · rdgdoc.xml · nonDerivative · entry 1 Schumacher Daniel · CIK 0001894753 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,297 Read SEC document |
| May 17, 2023 Filed May 19, 2023 16:11 UTC |
Greiner StacyDirector
|
GrantCommon Stock | 4,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-015291 · rdgdoc.xml · nonDerivative · entry 1 Greiner Stacy · CIK 0001894943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,004 F1 · shares: Deferred stock units that vest in full on the earlier of the first anniversary of the grant date or the date of the 2024 annual meeting of shareholders of Proto Labs, Inc. (the "Company"), but must be retained by the reporting person until the completion of the reporting person's service on the Company's Board of Directors. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:18 UTC |
Black Archie C.Director
|
GrantCommon Stock | 4,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-015300 · rdgdoc.xml · nonDerivative · entry 1 Black Archie C. · CIK 0001489095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,013 F1 · shares: Deferred stock units that vest in full on the earlier of the first anniversary of the grant date or the date of the 2024 annual meeting of shareholders of Proto Labs, Inc. (the "Company"), but must be retained by the reporting person until the completion of the reporting person's service on the Company's Board of Directors. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:17 UTC |
Chin MoonhieDirector
|
GrantCommon Stock | 4,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-015298 · rdgdoc.xml · nonDerivative · entry 1 Chin Moonhie · CIK 0001395001 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,456 F1 · shares: Deferred stock units that vest in full on the earlier of the first anniversary of the grant date or the date of the 2024 annual meeting of shareholders of Proto Labs, Inc. (the "Company"), but must be retained by the reporting person until the completion of the reporting person's service on the Company's Board of Directors. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:17 UTC |
Chand SujeetDirector
|
GrantCommon Stock | 4,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-015299 · rdgdoc.xml · nonDerivative · entry 1 Chand Sujeet · CIK 0001388884 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,013 F1 · shares: Deferred stock units that vest in full on the earlier of the first anniversary of the grant date or the date of the 2024 annual meeting of shareholders of Proto Labs, Inc. (the "Company"), but must be retained by the reporting person until the completion of the reporting person's service on the Company's Board of Directors. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:16 UTC |
Gawlick RainerDirector
|
GrantCommon Stock | 4,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-015297 · rdgdoc.xml · nonDerivative · entry 1 Gawlick Rainer · CIK 0001542473 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,528 F1 · shares: Deferred stock units that vest in full on the earlier of the first anniversary of the grant date or the date of the 2024 annual meeting of shareholders of Proto Labs, Inc. (the "Company"), but must be retained by the reporting person until the completion of the reporting person's service on the Company's Board of Directors. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:11 UTC |
WEHRWEIN SVENDirector
|
GrantCommon Stock | 4,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-015289 · rdgdoc.xml · nonDerivative · entry 1 WEHRWEIN SVEN · CIK 0001205069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,655 F1 · shares: Deferred stock units that vest in full on the earlier of the first anniversary of the grant date or the date of the 2024 annual meeting of shareholders of Proto Labs, Inc. (the "Company"), but must be retained by the reporting person until the completion of the reporting person's service on the Company's Board of Directors. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:10 UTC |
KRANTZ DONALD GDirector
|
GrantCommon Stock | 4,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-015287 · rdgdoc.xml · nonDerivative · entry 1 KRANTZ DONALD G · CIK 0001183159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,013 F1 · shares: Restricted stock units that vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2024 annual meeting of shareholders. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:09 UTC |
Kenison Michael R.VP and GM of the America's
|
GrantEmployee Stock Option (right to buy) · Derivative | 3,048 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001437749-23-003516 · rdgdoc.xml · derivative · entry 5 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,048 Underlying: Common Stock · 3,048 shares Expires 2026-02-14 F5 · derivative.exercise_date: The stock option vests in full on February 13, 2024. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:09 UTC |
Kenison Michael R.VP and GM of the America's
|
GrantEmployee Stock Option (right to buy) · Derivative | 7,712 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001437749-23-003516 · rdgdoc.xml · derivative · entry 4 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,712 Underlying: Common Stock · 7,712 shares Expires 2033-02-14 F4 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:09 UTC |
Kenison Michael R.VP and GM of the America's
|
GrantPerformance Stock Units · Derivative | 4,064 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-003516 · rdgdoc.xml · derivative · entry 3 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,064 Underlying: Common Stock · 4,064 shares Expires 2025-12-31 F3 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of Proto Labs, Inc. common stock. The performance stock units vest upon Proto Labs, Inc. common stock achieving a specified price per share. F3 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of Proto Labs, Inc. common stock. The performance stock units vest upon Proto Labs, Inc. common stock achieving a specified price per share. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:09 UTC |
Kenison Michael R.VP and GM of the America's
|
GrantCommon Stock | 8,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-003516 · rdgdoc.xml · nonDerivative · entry 2 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,724 F2 · shares: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:06 UTC |
Schumacher DanielChief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 3,135 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001437749-23-003513 · rdgdoc.xml · derivative · entry 5 Schumacher Daniel · CIK 0001894753 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,135 Underlying: Common Stock · 3,135 shares Expires 2026-02-14 F4 · derivative.exercise_date: The stock option vests in full on February 13, 2024. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:06 UTC |
Schumacher DanielChief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 9,815 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001437749-23-003513 · rdgdoc.xml · derivative · entry 4 Schumacher Daniel · CIK 0001894753 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,815 Underlying: Common Stock · 9,815 shares Expires 2033-02-14 F3 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:06 UTC |
Schumacher DanielChief Financial Officer
|
GrantPerformance Stock Units · Derivative | 10,343 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-003513 · rdgdoc.xml · derivative · entry 3 Schumacher Daniel · CIK 0001894753 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,343 Underlying: Common Stock · 10,343 shares Expires 2025-12-31 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of Proto Labs, Inc. common stock. The performance stock units vest upon Proto Labs, Inc. common stock achieving a specified price per share. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of Proto Labs, Inc. common stock. The performance stock units vest upon Proto Labs, Inc. common stock achieving a specified price per share. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:06 UTC |
Schumacher DanielChief Financial Officer
|
GrantCommon Stock | 5,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-003513 · rdgdoc.xml · nonDerivative · entry 2 Schumacher Daniel · CIK 0001894753 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,715 F1 · shares: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:06 UTC |
Ryaboy OlegChief Technology Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 3,048 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001437749-23-003512 · rdgdoc.xml · derivative · entry 5 Ryaboy Oleg · CIK 0001945827 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,048 Underlying: Common Stock · 3,048 shares Expires 2026-02-14 F4 · derivative.exercise_date: The stock option vests in full on February 13, 2024. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:06 UTC |
Ryaboy OlegChief Technology Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 9,815 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001437749-23-003512 · rdgdoc.xml · derivative · entry 4 Ryaboy Oleg · CIK 0001945827 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,815 Underlying: Common Stock · 9,815 shares Expires 2033-02-14 F3 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:06 UTC |
Ryaboy OlegChief Technology Officer
|
GrantPerformance Stock Units · Derivative | 5,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-003512 · rdgdoc.xml · derivative · entry 3 Ryaboy Oleg · CIK 0001945827 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,172 Underlying: Common Stock · 5,172 shares Expires 2025-12-31 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of Proto Labs, Inc. common stock. The performance stock units vest upon Proto Labs, Inc. common stock achieving a specified price per share. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of Proto Labs, Inc. common stock. The performance stock units vest upon Proto Labs, Inc. common stock achieving a specified price per share. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:06 UTC |
Ryaboy OlegChief Technology Officer
|
GrantCommon Stock | 10,343 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-003512 · rdgdoc.xml · nonDerivative · entry 2 Ryaboy Oleg · CIK 0001945827 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,863 F1 · shares: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:08 UTC |
Bodor RobertPresident and CEO
|
GrantEmployee Stock Option (right to buy) · Derivative | 10,448 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001437749-23-003515 · rdgdoc.xml · derivative · entry 5 Bodor Robert · CIK 0001581088 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,448 Underlying: Common Stock · 10,448 shares Expires 2026-02-14 F4 · derivative.exercise_date: The stock option vests in full on February 13, 2024. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:08 UTC |
Bodor RobertPresident and CEO
|
GrantEmployee Stock Option (right to buy) · Derivative | 42,061 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001437749-23-003515 · rdgdoc.xml · derivative · entry 4 Bodor Robert · CIK 0001581088 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,061 Underlying: Common Stock · 42,061 shares Expires 2033-02-14 F3 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:08 UTC |
Bodor RobertPresident and CEO
|
GrantPerformance Stock Units · Derivative | 44,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-003515 · rdgdoc.xml · derivative · entry 3 Bodor Robert · CIK 0001581088 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,327 Underlying: Common Stock · 44,327 shares Expires 2025-12-31 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of Proto Labs, Inc. common stock. The performance stock units vest upon Proto Labs, Inc. common stock achieving a specified price per share. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of Proto Labs, Inc. common stock. The performance stock units vest upon Proto Labs, Inc. common stock achieving a specified price per share. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:08 UTC |
Bodor RobertPresident and CEO
|
GrantCommon Stock | 22,164 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-003515 · rdgdoc.xml · nonDerivative · entry 2 Bodor Robert · CIK 0001581088 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,778 F1 · shares: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:05 UTC |
Klaas BjoernVP and Mng Director-PL Europe
|
GrantEmployee Stock Option (right to buy) · Derivative | 3,048 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001437749-23-003511 · rdgdoc.xml · derivative · entry 5 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,048 Underlying: Common Stock · 3,048 shares Expires 2026-02-14 F4 · derivative.exercise_date: The stock option vests in full on February 13, 2024. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:05 UTC |
Klaas BjoernVP and Mng Director-PL Europe
|
GrantEmployee Stock Option (right to buy) · Derivative | 6,310 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001437749-23-003511 · rdgdoc.xml · derivative · entry 4 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,310 Underlying: Common Stock · 6,310 shares Expires 2033-02-14 F3 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:05 UTC |
Klaas BjoernVP and Mng Director-PL Europe
|
GrantPerformance Stock Units · Derivative | 3,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-003511 · rdgdoc.xml · derivative · entry 3 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,325 Underlying: Common Stock · 3,325 shares Expires 2025-12-31 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of Proto Labs, Inc. common stock. The performance stock units vest upon Proto Labs, Inc. common stock achieving a specified price per share. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of Proto Labs, Inc. common stock. The performance stock units vest upon Proto Labs, Inc. common stock achieving a specified price per share. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:05 UTC |
Klaas BjoernVP and Mng Director-PL Europe
|
GrantCommon Stock | 6,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-003511 · rdgdoc.xml · nonDerivative · entry 2 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,074 F1 · shares: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:09 UTC |
Kenison Michael R.VP and GM of the America's
|
Tax withholdingCommon Stock | 340 | $34.23 | $11,638.20 |
DisclosureSEC source: 0001437749-23-003516 · rdgdoc.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,597 F1 · balance_after: Includes 262 shares of Common Stock of the issuer purchased on November 15, 2022 through the issuer's Employee Stock Purchase Plan program. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:06 UTC |
Schumacher DanielChief Financial Officer
|
Tax withholdingCommon Stock | 553 | $34.23 | $18,929.19 |
DisclosureSEC source: 0001437749-23-003513 · rdgdoc.xml · nonDerivative · entry 1 Schumacher Daniel · CIK 0001894753 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,543 Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:06 UTC |
Ryaboy OlegChief Technology Officer
|
Tax withholdingCommon Stock | 841 | $34.23 | $28,787.43 |
DisclosureSEC source: 0001437749-23-003512 · rdgdoc.xml · nonDerivative · entry 1 Ryaboy Oleg · CIK 0001945827 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,520 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.